Article PDF
Literatur
Mihindukulasuriya KA, Nguyen NL, Wu G et al (2009) Nyamanini and midway viruses define a novel taxon of RNA viruses in the order Mononegavirales. J Virol 83:5109–5116
Anthony SM, Bradfute SB (2015) Filoviruses: One of these things is (not) like the other. Viruses 7:5172–5190
Bào Y, Amarasinghe GK, Basler CF et al (2017) Implementation of objective PASC-derived taxon demarcation criteria for official classification of filoviruses. Viruses 9:E106
Brauburger K, Hume AJ, Mühlberger E, Olejnik J (2012) Forty-five years of Marburg virus research. Viruses 4:1878–1927
Burk R, Bollinger L, Johnson JC et al (2016) Neglected filoviruses. FEMS Microbiol Rev 40:494–519
Kuhn JH, Becker S, Ebihara H et al (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155:2083–2103
Kuhn JH, Andersen KG, Bào Y et al (2014) Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses 6:3663–3682
Negredo A, Palacios G, Vázquez-Morón S et al (2011) Discovery of an Ebolavirus-like filovirus in Europe. Plos Pathog 7:e1002304
Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM (2015) Ebola and Marburg haemorrhagic fever. J Clin Virol 64:111–119
Messaoudi I, Amarasinghe GK, Basler CF (2015) Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol 13:663–676
Siegert R, Shu HL, Slenczka W, Peters D, Müller G (1967) Zur Ätiologie einer unbekannten, von Affen ausgegangenen menschlichen Infektionskrankheit. Dtsch Med Wochenschr 92:2341–2343
WHO-Zaire (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56:271–293
Johnson KM, Lange JV, Webb PA, Murphy FA (1977) Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 309:569–571
WHO-Sudan (1978) Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56:247–270
Johnson ED, Johnson BK, Silverstein D et al (1996) Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch Virol Suppl 11:S101–S114
Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C (1995) Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345:1271–1274
Muyembe-Tamfum JJ, Kipasa M, Kiyungu C, Colebunders R (1999) Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. J Infect Dis 179 Suppl 1:259–S262
Formella M, Gatherer D (2016) The serology of Ebolavirus – a wider geographical range, a wider genus of viruses or a wider range of virulence? J Gen Virol 97:3120–3130
Pigott DM, Golding N, Mylne A et al (2014) Mapping the zoonotic niche of Ebola virus disease in Africa. Elife 3:e04395
Pigott DM, Golding N, Mylne A et al (2015) Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg 109:366–378
Pigott DM, Millear AI, Earl L et al (2016) Updates to the zoonotic niche map of Ebola virus disease in Africa. Elife 5:e16412
Coltart CEM, Lindsey B, Ghinai I, Johnson AM, Heyman DL (2017) The Ebola outbreak, 2013–2016: old lessons for new epidemics. Philos Trans R Soc London B Biol Sci 372:20160297
Geisbert TW, Jahrling PB (1990) Use of immunoelectron microscopy to show Ebola virus during the 1989 United States epizootic. J Clin Pathol 43:813–816
Wertheim JO, Kosakovsky Pond SL (2011) Purifying selection can obscure the ancient age of viral lineages. Mol Biol Evol 28:3355–3365
Belyi VA, Levine AJ, Skalka AM (2010) Unexpected inheritance: multiple integrations of ancient bornavirus and Ebolavirus/Marburgvirus sequences in vertebrate genomes. Plos Pathog 6:e1001030
Taylor DJ, Leach RW, Bruenn J (2010) Filoviruses are ancient and integrated into mammalian genomes. BMC Evol Biol 10:193
De La Vega MA, Stein D, Kobinger GP (2015) Ebolavirus evolution: past and present. Plos Pathog 11:e1005221
Li YH, Chen SP (2014) Evolutionary history of Ebola virus. Epidemiol Infect 142:1138–1145
Carroll SA, Towner JS, Sealy TK et al (2013) Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences. J Virol 87:2608–2616
Gire SK, Goba A, Andersen KG et al (2014) Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369–1372
Dudas G, Carvalho LM, Bedford T et al (2017) Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature 544:309–315
Simon-Loriere E, Faye O, Faye O et al (2015) Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic. Nature 524:102–104
Mühlberger E (2007) Filovirus replication and transcription. Future Virol 2:205–215
Jun SR, Leuze MR, Nookaew I et al (2015) Ebolavirus comparative genomics. FEMS Microbiol Rev 39:764–778
Yusim K, Yoon H, Foley B et al (2016) Integrated sequence and immunology filovirus database at Los Alamos. Database (Oxford) 2016:baw47
Falasca L, Agrati C, Petrosillo N et al (2015) Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ 22:1250–1259
Banadyga L, Dolan MA, Ebihara H (2016) Rodent-adapted filoviruses and the molecular basis of pathogenesis. J Mol Biol 428:3449–3466
Collar AL, Clarke EC, Anaya E et al (2017) Comparison of N- and O-linked glycosylation patterns of ebolavirus glycoproteins. Virology 502:39–41
Bosworth A, Dowall SD, Garcia-Dorival I et al (2017) A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus. Sci Rep 7:43144
Geisbert TW, Hensley LE, Larsen T et al (2003) Pathogenesis of Ebola hemorrhagic fever in Cynomolgus macaques : evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347–2370
Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377:849–862
Janvier F, Delaune D, Poyot T et al (2016) Ebola virus RNA stability in human blood and urine in West Africa’s environmental conditions. Emerg Infect Dis 22:292–294
Bibby K, Fischer PJ, Casson LW, Stachler E, Haas CN, Munster VJ (2015) Persistence of Ebola virus in sterilized wastewater. Environ Sci Technol Lett 2:245–249
Fischer RJ, Judson SD, Miazgowicz K, Bushmaker T, Prescott JB, Munster VJ (2015) Ebola virus stability on surfaces and in fluids in simulated outbreak environments. Emerg Infect Dis 21:1243–1246
Westhoff Smith D, Hill-Batorski L, N'jai A et al (2016) Ebola virus stability under hospital and environmental conditions. J Infect Dis 214(suppl 3):S142–S144
Schuit M, Miller DM, Reddick-Elick MS et al (2016) Differences in the comparative stability of Ebola virus Makona-C05 and Yambuku-Mayinga in blood. PLoS ONE 11:e0148476
Piercy TJ, Smither SJ, Steward JA, Eastaugh L, Lever MS (2010) The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol 109:1531–1539
Cook BWM, Cutts TA, Nikiforuk AM et al (2015) Evaluating environmental persistence and disinfection of the Ebola virus Makona variant. Viruses 7:1975–1986
Sagripanti JL, Rom AM, Holland LE (2010) Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Arch Virol 155:2035–2039
Prescott JB, Bushmaker T, Fischer RJ, Miazgowicz K, Judson SD, Munster VJ (2015) Postmortem stability of Ebola virus. Emerg Infect Dis 21:856–859
Cook BWM, Cutts TA, Nikiforuk AM, Leung A, Kobasa D, Theriault SS (2016) The disinfection characteristics of Ebola virus outbreak variants. Sci Rep 6:38293
Cutts T, Cook B, Poliquin G, Strong J, Theriault S (2016) Inactivating Zaire Ebolavirus in whole-blood thin smears used for malaria diagnosis. J Clin Microbiol 54:1157–1159
Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, Chepurnova TS, Baker JR Jr (2003) Inactivation of Ebola virus with a surfactant nanoemulsion. Acta Trop 87:315–320
Jinadatha C, Simmons S, Dale C et al (2015) Disinfecting personal protective equipment with pulsed xenon ultraviolet as a risk mitigation strategy for health care workers. Am J Infect Control 43:412–414
Mifsud A, Peelen D, Brincat P et al (2016) A feasibility study on the effects of Triton X-100 for the in vitro inactivation of Ebola virus on haematological assays. J Clin Pathol 69:637–642
Cutts T, Grolla A, Jones S, Cook BWM, Qiu X, Theriault SS (2016) Inactivation of Zaire ebolavirus variant Makona in human serum samples analyzed by enzyme-linked immunosorbent assay. J Infect Dis 214 Suppl 3:218–S221
van Kampen JJA, Tintu A, Russcher H et al (2017) Ebola Virus Inactivation by Detergents Is Annulled in Serum. J Infect Dis 216:859–866
Haddock E, Feldmann F, Feldmann H (2016) Effective chemical inactivation of Ebola virus. Emerg Infect Dis 22:1292–1294
Smither SJ, Weller SA, Phelps A et al (2015) Buffer AVL alone does not inactivate Ebola virus in a representative clinical sample type. J Clin Microbiol 53:3148–3154
Leroy EM, Baize S, Volchkov VE et al (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355:2210–2215
Francesconi P, Yoti Z, Declich S et al (2003) Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 9:1430–1437
Bausch DG, Towner JS, Dowell SF et al (2007) Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196 Suppl 2:142–S147
Osterholm MT, Moore KA, Kelley NS et al (2015) Transmission of Ebola viruses: what we know and what we do not know. MBio 6:e00137–15
Franz DR, Jahrling PB, Friedlander AM et al (1997) Clinical recognition and management of patients exposed to biological warfare agents. J Am Med Ass 278:399–411
Faye O, Boëlle PY, Heleze E et al (2015) Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study. Lancet Infect Dis 15:320–326
Dean NE, Halloran ME, Yang Y, Longini IM (2016) Transmissibility and pathogenicity of Ebola virus: A systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin Infect Dis 62:1277–1286
Bower H, Glynn JR (2017) A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection. Sci Data 4:160133
Becquart P, Wauquier N, Mahlakõiv T et al (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE 5:e0009126
Hayes CG, Burans JP, Ksiazek TG et al (1992) Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus. Am J Trop Med Hyg 46:664–671
Harrod KS (2015) Ebola: history, treatment, and lessons from a new emerging pathogen. Am J Physiol Lung Cell Mol Physiol 308:L307–L313
Cantoni D, Hamlet A, Michaelis M, Wass MN, Rossman JS (2016) Risks posed by Reston, the forgotten Ebolavirus. mSphere 1:e00322–16
Miranda MEG, Miranda NLJ (2011) Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 204 Suppl 3:S757–S760
Gralton J, Tovey E, McLaws ML, Rawlinson WD (2011) The role of particle size in aerosolised pathogen transmission: a review. J Infect 62:1–13
Glynn JR, Bower H, Johnson S et al (2017) Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infect Dis 17:645–653
Johnson E, Jaax N, White J, Jahrling P (1995) Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 76:227–236
Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK (2011) Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 13:930–936
Zumbrun EE, Abdeltawab NF, Bloomfield HA et al (2012) Development of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred mice. Viruses 4:3468–3493
Jaax N, Jahrling P, Geisbert T et al (1995) Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669–1671
Mann E, Streng S, Bergeron J, Kircher A (2015) A review of the role of food and the food system in the transmission and spread of Ebolavirus. Plos Negl Trop Dis 9:e0004160
Aylward B, Barboza P, Bawo L et al, WHO Ebola Response Team (2014) Ebola virus disease in West Africa – the first 9 months of the epidemic and forward projections. N Engl J Med 371:1481–1495
Fischer WA 2nd, Wohl DA (2016) Confronting Ebola as a sexually transmitted infection. Clin Infect Dis 62:1272–1276
El Sayed SM, Abdelrahman AA, Ozbak HA et al (2015) Updates in diagnosis and management of Ebola hemorrhagic fever. J Res Med Sci 21:84
Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG (2016) Post-Ebola syndrome, Sierra Leone. Emerg Infect Dis 22:641–646
Hartley MA, Young A, Tran AM et al (2017) Predicting Ebola severity: a clinical prioritization score for Ebola virus disease. PLoS Negl Trop Med 11:e0005265
Waxman M, Aluisio AR, Rege S, Levine AC (2017) Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study. Lancet Infect Dis 17:654–660
Bower H, Smout E, Bangura MS et al (2016) Deaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort study. Br Med J 353:i2403
Garske T, Cori A, Ariyarajah A et al (2017) Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013–2016. Philos Trans R Soc Lond B Biol Sci 372:20160308
Rasmussen AL (2016) Host factors in Ebola infection. Annu Rev Genomics Hum Genet 17:333–351
Tiffany A, Vetter P, Mattia J et al (2016) Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin Infect Dis 62:1360–1366
Gear JSS, Cassel GA, Gear AJ et al (1975) Outbreak of Marburg virus disease in Johannesburg. Br Med J 4:489–493
McElroy AK, Erickson BR, Flietstra TD et al (2014) Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 210:558–566
Lanini S, Portella G, Vairo F et al (2015) Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest 125:4692–4698
Rudolf F, Damkjaer M, Lunding S et al (2017) Influence of referral pathway on Ebola virus disease case–fatality rate and effect of survival selection bias. Emerg Infect Dis 23:597–600
Sagui E, Janvier F, Baize S et al (2015) Severe Ebola virus infection with encephalopathy: evidence for direct virus involvement. Clin Infect Dis 61:1627–1628
Geisen C, Kann G, Strecker T et al (2016) Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies. Vox Sang 110:329–335
Brainard J, Pond K, Hooper L, Edmunds K, Hunter P (2016) Presence and persistence of Ebola or Marburg virus in patients and survivors: a rapid systematic review. Plos Negl Trop Dis 10:e0004475
Deen GF, Broutet N, Xu W et al (2017) Ebola RNA persistence in semen of Ebola virus disease survivors – final report. N Engl J Med 377:1428–1437
Uyeki TM, Erickson BR, Brown S et al (2016) Ebola virus persistence in semen of male survivors. Clin Infect Dis 62:1552–1555
Sissoko D, Duraffour S, Kerber R et al (2017) Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob Health 5:e80–e88
Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch DG (2016) Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis 16:e82–e91
Varkey JB, Shantha JG, Crozier I et al (2015) Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 372:2423–2427
Sissoko D, Keïta M, Diallo B et al (2017) Ebola virus persistence in breast milk after no reported illness: a likely source of virus transmission from mother to child. Clin Infect Dis 64:513–516
Amman BR, Carrol SA, Reed ZD et al (2012) Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. Plos Pathog 8:e1002877
Olival KJ, Hayman DTS (2014) Filoviruses in bats: current knowledge and future directions. Viruses 6:1759–1788
Jones MEB, Schuh AJ, Amman BR et al (2015) Experimental inoculation of Egyptian Rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera. Viruses 7:3420–3442
Leroy EM, Rouquet P, Formenty P et al (2004) Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303:387–390
Smither SJ, Nelson M, Eastaugh L, Nunez A, Salguero FJ, Lever MS (2015) Experimental respiratory infection of marmosets (Callithrix jacchus) with Ebola virus Kikwit. J Infect Dis 212 (Suppl 2):S336–S345
Swanepoel R, Leman PA, Burt FJ et al (1996) Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 2:321–325
Urbanowicz RA, McClure CP, Sakuntabhai A et al (2016) Human adaptation of Ebola virus during the West African outbreak. Cell 167:1079–1087
Holmes EC, Dudas G, Rambaut A, Andersen KG (2016) The evolution of Ebola virus: Insights from the 2013–2016 epidemic. Nature 538:193–200
Smith DW, Rawlinson WD, Kok J, Dwyer DE, Catton M (2015) Virological diagnosis of Ebolavirus infection. Pathology 47:410–413
Su S, Wong G, Qiu X, Kobinger G, Bi Y, Zhou J (2016) Diagnostic strategies for Ebola virus detection. Lancet Infect Dis 16:294–295
Ksiazek TG, Rollin PE, Jahrling PB, Johnson E, Dalgard DW, Peters CJ (1992) Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol 30:947–950
Urassa W, Meurant R, Wood D (2015) ReEBOV Antigen Rapid Test kit for Ebola. Lancet 386:2253–2254
Rowe AK, Bertolli J, Khan AS et al (1999) Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les epidémies à Kikwit. J Infect Dis 179 (Suppl 1):S28–S35
Broadhurst MJ, Kelly JD, Miller A et al (2015) ReEBOV antigen rapid test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet 386:867–874
Cross RW, Boisen ML, Millett MM et al (2016) Analytical validation of the ReEBOV antigen rapid test for point-of-care diagnosis of Ebola virus infection. J Infect Dis 214 Suppl 3:S210–S217
Yoshida R, Muramatsu S, Akita H et al (2016) Development of an immunochromatography assay (QuickNavi-Ebola) to detect multiple species of Ebolaviruses. J Infect Dis 214 (Suppl 3):S185–S191
Spinner ML, di Giovanni GD (2001) Detection and identification of mammalian reoviruses in surface water by combined cell culture and reverse transcription-PCR. Appl Environ Microbiol 67:3016–3020
Cherpillod P, Schibler M, Vieille G et al (2016) Ebola virus disease diagnosis by real-time RT-PCR: a comparative study of 11 different procedures. J Clin Virol 77:9–14
Towner JS, Rollin PE, Bausch DG et al (2004) Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78:4330–4341
Jansen van Vuren P, Grobbelaar A, Storm N et al (2016) Comparative evaluation of the diagnostic performance of the prototype Cepheid GeneXpert Ebola assay. J Clin Microbiol 54:359–367
Van den Bergh R, Chaillet P, Sow MS et al (2016) Feasibility of Xpert Ebola assay in Médicins Sans Frontières Ebola Program, Guinea. Emerg Infect Dis 22:210–216
Semper AE, Broadhurst MJ, Richards J et al (2016) Performance of the GeneXpert Ebola assay for diagnosis of Ebola virus disease in Sierra Leone: a field evaluation study. Plos Med 13:e1001980
Loftis AJ, Quellie S, Chason K et al (2017) Validation of the Cepheid GeneXpert for detecting Ebola virus in semen. J Infect Dis 215:344–350
Ro YT, Ticer A, Carrion R Jr, Patterson JL (2017) Rapid detection and quantification of Ebola Zaire virus by one-step real-time quantitative reverse transcription-polymerase chain reaction. Microbiol Immunol 61:130–137
Kurosaki Y, Grolla A, Fukuma A, Feldmann H, Yasuda J (2010) Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method. J Clin Microbiol 48:2330–2336
Xu C, Wang H, Jin H et al (2016) Visual detection of Ebola virus using reverse transcription loop-mediated isothermal amplification combined with nucleic acid strip detection. Arch Virol 161:1125–1133
Lu G, Zhang J, Zhang C et al (2015) One-step reverse-transcription FRET-PCR for differential detection of five Ebolavirus species. PLoS ONE 10:e0126281
Bergqvist C, Holmström P, Lindegren G, Lagerqvist N, Leijon M, Falk KI (2015) Multiplex nucleic acid suspension bead arrays for detection and subtyping of filoviruses. J Clin Microbiol 53:1368–1370
Fang LQ, Yang Y, Jiang JF et al (2016) Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone. Proc Natl Acad Sci USA 113:4488–4493
Agua-Agum J, Allegranzi B et al, WHO Ebola Response Team (2016) After Ebola in West Africa – unpredictable risks, preventable epidemics. N Engl J Med 375:587–596
Hersi M, Stevens A, Quach P et al (2015) Effectiveness of personal protective equipment for healthcare workers caring for patients with filovirus disease: a rapid review. PLoS ONE 10:e0140290
Wong G, Kobinger GP (2015) Backs against the wall: novel and existing strategies used during the 2014–2015 Ebola virus outbreak. Clin Microbiol Rev 28:593–601
Fock R, Koch U, Wirtz A, Peters M, Ruf B, Grünwald T (2001) Erste medizinische und antiepidemische Maßnahmen bei Verdacht auf virales hämorrhagisches Fieber. Med Welt 52:126–132
Robert Koch-Institut (2014) Zum Ebolafieber-Ausbruch in Afrika. Epid Bull 35(Supplement):S1–S2
Moyen N, Thirion L, Emmerich P et al (2015) Risk factors associated with Ebola and Marburg viruses seroprevalence in blood donors in the Republic of Congo. Plos Negl Trop Dis 9:e0003833
Tomori O, Fabiyi A, Sorungbe A, Smith A, McCormick JB (1988) Viral hemorrhagic fever antibodies in Nigerian populations. Am J Trop Med Hyg 38:407–410
Bouree P, Bergmann JF (1983) Ebola virus infection in man: a serological and epidemiological survey in the Cameroons. Am J Trop Med Hyg 32:1465–1466
Van Griensven J, Edwards T, de Lamballerie X et al (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374:33–42
Kreil TR (2015) Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis 21:521–523
van Griensven J, De Weiggheleire A, Delamou A et al (2016) The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. Clin Infect Dis 62:69–74
Arribas JR, Luczkowiak J, Delgado R (2016) Convalescent plasma for Ebola virus disease. N Engl J Med 374:2498–2499
Moekotte AL, Huson MAM, van der Ende AJ et al (2016) Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opin Investig Drugs 25:1325–1335
Rojek A, Horby P, Dunning J (2017) Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infect Dis 17:e280–e292
Kraft CS, Hewlett AL, Koepsell S et al (2015) The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 61:496–502
Garraud O (2017) Use of convalescent plasma in Ebola virus infection. Transfus Apher Sci 56:31–34
Koepsell SA, Winkler AM, Roback JD (2017) The role of the laboratory and transfusion service in the management of Ebola virus disease. Transfus Med Rev 31:149–153
Bixler SL, Duplantier AJ, Bavari S (2017) Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis 9:299–317
Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G et al (2015) Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 3:554–562
Rhein BA, Powers LS, Rogers K et al (2015) Interferon-γ inhibits Ebola virus infection. Plos Pathog 11:e1005263
Konde MK, Baker DP, Traore FA et al (2017) Interferon β-1a for the treatment of Ebola virus disease: a historically controlled, single-arm proof-of-concept trial. PLoS ONE 12:e0169255
Tran EEH, Nelson EA, Bonagiri P et al (2016) Mapping of Ebolavirus neutralization by monoclonal antibodies in the ZMapp cocktail using cryo-electron tomography and studies of cellular entry. J Virol 90:7618–7627
Qiu X, Wong G, Audet J et al (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53
Murin CD, Fusco ML, Bornholdt ZA et al (2014) Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA 111:17182–17187
Lyon GM, Mehta AK, Varkey JB et al (2014) Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371:2402–2409
Corti D, Misasi J, Mulangu S et al (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351:1339–1342
Davidson E, Bryan C, Fong RH et al (2015) Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol 89:10982–10992
Furuyama W, Marzi A, Nanbo A et al (2016) Discovery of an antibody for pan-ebolavirus therapy. Sci Rep 6:20514
Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT Jr, Beigel JH (2016) Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med 22:1439–1447
Haque A, Hober D, Blondiaux J (2015) Addressing therapeutic options for Ebola virus infection in current and future outbreaks. Antimicrob Agents Chemother 59:5892–5902
Warren TK, Wells J, Panchal RG et al (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402–405
Warren TK, Jordan R, Lo MK et al (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–385
Cong Y, Dyall J, Hart BJ et al (2016) Evaluation of the activity of lamivudine and zidovudine against Ebola virus. PLoS ONE 11:e0166318
Falzarano D (2016) Ebola vaccines: we have options. Lancet Infect Dis 16:267–268
Henao-Restrepo AM, Longini IM, Egger M et al (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857–866
Friedrich BM, Trefry JC, Biggins JE et al (2012) Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4:1619–1650
Mire CE, Geisbert TW, Feldmann H, Marzi A (2016) Ebola virus vaccines – reality or fiction? Expert Rev Vaccines 15:1421–1430
Venkatraman N, Silman D, Folegatti PM, Hill AVS (2017) Vaccines against Ebola virus. Vaccine. https://doi.org/10.1016/j.vaccine.2017.07.054
Holtsberg FW, Shulenin S, Vu H et al (2016) Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J Virol 90:266–278
Schweneker M, Laimbacher AS, Zimmer G et al (2017) Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles. J Virol 91:e00343–17
Blaney JE, Marzi A, Willet M et al (2013) Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. Plos Pathog 9:e1003389
Huttner A, Dayer JA, Yerly S et al (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15:1156–1166
De Santis O, Audran R, Pothin E et al (2016) Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomized, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 16:311–320
Tapia MD, Sow SO, Lyke KE et al (2016) Use of CHAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16:31–42
Dolzhikova IV, Zubkova OV, Tukhvatulin AI et al (2017) Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother 13:613–620
Lehrer AT, Wong TS, Lieberman MM et al (2018) Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice. Vaccine 36:3090–3100
Elliott LE, McCormick JB, Johnson KM (1982) Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 16:704–708
Sagripanti JL, Lytle CD (2011) Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. Arch Virol 156:489–494
Cap AP, Pidcoke HF, Keil SD et al (2016) Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 56 Suppl 1:S6–S15
Rights and permissions
About this article
Cite this article
Filovirus – Auslöser von hämorrhagischem Fieber. Bundesgesundheitsbl 61, 894–907 (2018). https://doi.org/10.1007/s00103-018-2757-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00103-018-2757-4